Acadia Pharmaceuticals focuses on neuroscience and provides FDA-approved treatments for conditions such as Parkinson's disease psychosis and Rett syndrome, while developing novel therapies for neurological disorders.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

COM:ACADIA

Acadia Pharmaceuticals

Last Close

15.79

07/11 21:00

Market Cap

2.83B

Beta: -

Volume Today

3.22M

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics